Drug Development - Novel Targets Milestones
6.A-6.J
No filters selected
ID
Title
Status
6.A
Drug Development/Novel Targets: Establish research database
Establish a searchable, open access research database that contains all clinical, biomarker, and epidemiological data, and related genotypes and phenotypes from existing genetic studies…
Status
Achieved
6.B
Drug Development/Novel Targets: Genomic efforts
Establish a consortium of genetics and genomics experts to develop and execute a large scale sequencing project to analyze the genomes of a large number of well characterized individuals…
Status
Achieved
6.C
Drug Development/Novel Targets: Target validation
Identify, characterize, and complete early validation for at least 6 novel therapeutic targets for AD and AD-related dementias…
Status
Achieved
6.D
Drug Development/Novel Targets: Novel therapeutic agents
Initiate drug discovery efforts to develop novel therapeutic agents against at least 6 novel therapeutic targets...
Status
In Progress
6.E
Drug Development/Novel Targets: Phase 1 trials
Initiate first in human, Phase 1 drug trials for therapeutic agents against at least 6 novel therapeutic targets...
Status
In Progress
6.F
Drug Development/Novel Targets: Phase 2 trials
Initiate Phase 2 (proof of concept) drug trials for agents against 3-6 novel therapeutic targets...
Status
In Progress
6.G
Drug Development/Novel Targets: Phase 3 trials
Initiate Phase 3 drug trials for agents against at least 3 novel therapeutic targets...
Status
To Be Initiated
6.H
Drug Development/Novel Targets: Mechanisms of non-pharmacological interventions
Initiate interdisciplinary research programs that integrate clinical, genomic and mechanistic research...
Status
In Progress
6.I
FTD: Genetics and epigenetics
Expand efforts to genotype patients with FTD and identify new genes and their functional relationship to FTLD pathogenesis.
Status
In Progress
6.J
Drug Development/Novel Targets: Resilience-based therapeutics
Support a diverse portfolio of candidate therapeutics including reversal or regenerative therapeutics for the treatment of advanced disease.
Status
To Be Initiated